GlassScriptPhysician profile
Tanya Reznick
NPI 1760896930
$917.98
in general payments reported to CMS, 2019-2025
11 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.27 · 2020: $44.78 · 2021: $17.41 · 2022: $100 · 2023: $68.32 · 2024: $128 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $374.70 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $171.40 | 2020-2025 | Omnipod |
| Beta Bionics, INC. | $137.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $49.69 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $49.01 | 2019-2022 | |
| Abbvie INC. | $32.93 | 2023 | |
| Dexcom, INC. | $32.28 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $21.15 | 2023 | |
| Medtronic, INC. | $17.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.08 | 2024 | |
| Sequel Med Tech, LLC | $14.79 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Reznick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.